Has my liver got diabetes? Fib4 score as a screening marker for early detection of non-alcoholic fatty liver disease (NAFLD) for patients with type 2 diabetes
No Thumbnail Available
Authors
Zeeshan , A
Powney , R
Housley , D
Khana, P
Sen, S
Wong , K
Soo , S
Issue Date
2022
Type
Scientific Paper
Language
Keywords
Research Subject Categories::MEDICINE::Dermatology and venerology,clinical genetics, internal medicine::Internal medicine::Endocrinology
Alternative Title
Abstract
A3 (P141)
Has my liver got diabetes? Fib4 score as a screening marker for early detection of non-alcoholic fatty liver disease (NAFLD) for patients with type 2 diabetes
A. Zeeshan1; R. Powney2; D. Housley2; P. Khana3; S. Sen3; K. Wong1; S. Soo1
1Department of Diabetes and Endocrinology, Luton and Dunstable Hospital, Bedfordshire, UK; 2Department of Biochemistry, Luton and Dunstable Hospital, Bedfordshire, UK; 3Department of Hepatology, Luton and Dunstable Hospital, Bedfordshire, UK
Background: NAFLD is increasingly common among patients with type 2 diabetes due to its strong association with obesity. NAFLD can potentially progress to liver cirrhosis, liver cancer and eventually liver failure. Therefore, early detection of NAFLD is vital to prompt further investigation and for consideration of treatment. At Luton & Dunstable Hospital, we started using FIB4 score for NAFLD risk stratification since December 2019.
Aim: To review the effectiveness of FIB4 in detection of NAFLD and to follow up on outcome following FIB4 testing
Methods: Prospective data collection of FIB4 test ordered by the Diabetes department for 12 months from December 2019.
Results: Total 144 Fib4 tests were requested for patients with type 2 diabetes over the period of one year. 4 patients (2.7%) were found to be high risk for NAFLD, 15(10.4 %) had medium risk and 126 (87.5%) were found to be in low risk category. All 19 patients in medium and high-risk category had been referred to hepatology for further assessment. At the time of analysis, 17 patients had been reviewed and 2 still awaiting an appointment. 10 patients out of 17 had fibroscan and liver biopsy. 5 out of 10 (50 %) patients had evidence of severe fibrosis and 1 patient was diagnosed with liver cirrhosis and rest of them had moderate liver fibrosis. We also feedback to individual patient consultant to consider further intensifying treatment to tighten glycaemic control
Conclusion: Fib4 score is an effective marker for risk stratification of NAFLD and very useful to detect NAFLD to prompt investigation and treatment at an early stage.
Description
Citation
Zeeshan, A., Powney, R., Housley, D., Khana, P., Sen, S., Wong, K., Soo, S. (2022) Has my liver got diabetes? Fib4 score as a screening marker for early detection of non-alcoholic fatty liver disease (NAFLD) for patients with type 2 diabetes. Diabetic Medicine. 39(Suppl 1). DOI: https://dx.doi.org/10.1111/dme.14809